New ESC Guidelines Recommend Efient® (Prasugrel) as First-line Antiplatelet Therapy for Patients with Non-ST Segment Myo

The company's world headquarters are in Tokyo. Its European base is located in Munich. DAIICHI SANKYO EUROPE has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

This press release contains certain forward-looking statements about prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that the product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.

Efient(R) is a registered trademark of Eli Lilly and Company.

References

(1) The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without ST-segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. Published online 26 August 2011. Available at: http://www.escardio.org/guidelines-surveys/esc-guidelines/Gu...

(2) Grech ED et al. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction.BMJ 2003; 326: 1259-1261

(3) Wijins W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2010; 31: 2501-2555

(4) Wiviott et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-15

(5) Efient (prasugrel) prescribing information EU. Daiichi Sankyo, Inc. and Eli Lilly and Company

(6) 2011 ACCF/AHA Focused update of the guidelines for the management of patients with unstable angina/non-ST elevation myocardial infarction (Updated 2007 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

(7) British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008. http://www.ehnheart.org Accessed August 2011

(8) Roger VL, Go AS, Lloyd-Jones DM, et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2011 update. Circulation. 2011;123:e1-e192.

(9) WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease. http://www.webmd.com. Accessed August 2011

(Logo: http://photos.prnewswire.com/prnh/201103... )

CONTACT: Christina D. Gaines, APR, Eli Lilly and Company, +1-317-276-3845(office), +1-317-366-2568 (cell); Dr. Michaela Paudler-Debus, DaiichiSankyo Europe GmbH, +49-(0)89-78-08-685 (office), +49-(0)172-845-8974(cell); Kimberly Wix, Daiichi Sankyo, Inc., +1-973-944-2338 (office),+1-908-656-5447 (cell)